Vitrafy Life Sciences Limited | Level 11, 385 Bourke Street, Melbourne VIC 3000 | ABN 48 622 720 254 T +61 3 4331 9974 | W www.vitrafy.com | E [email protected] ASX ANNOUNCEMENT 7 October 2026 Change to Chief Executive Officer Remuneration and Employment Terms Vitrafy Life Sciences Limited...
Change to CEO Remuneration and Employment Terms
Filed with ASX · · 4 pages · English
Release
Vitrafy Life Sciences Ltd. on 6ix
In the deck
Earlier from Vitrafy Life Sciences
- Vitrafy enters partnership with Versiti Blood Health
- S&P DJI Announces September 2026 Quarterly Rebalance
- Vitrafy enters U.S. Cell & Gene Therapy Market
- FY26 Full Year Results Presentation
- FY26 Appendix 4E and Annual Report
Later from Vitrafy Life Sciences
- Investor Roadshow Presentation
- 2026 Notice of Annual General Meeting
- Appointment of Chief Financial Officer
- Application for quotation of securities - VFY
- Vitrafy Q1 FY27 Investor Briefing
Follow Vitrafy Life Sciences into a list and get an email when it puts out news.
Follow Vitrafy Life Sciences